NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03104439 2026-01-12
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT07226856 2025-12-22
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting
NCT02451982 2025-12-03
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT06941857 2025-12-03
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03697564 2025-08-06
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
University of California, San Diego
Phase 2 Completed
NCT03250273 2025-05-28
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03161379 2025-02-03
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03190265 2024-08-07
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05116917 2024-05-28
INFLUENCE
Herlev Hospital
Phase 2 Terminated
NCT02866383 2023-09-22
CheckPAC
Herlev Hospital
Phase 2 Completed
NCT05435053 2023-09-15
CHECKPOINT
Zealand University Hospital
Phase 2 Terminated
NCT04953962 2023-08-15
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
CanBas Co. Ltd.
Phase 2 Completed
NCT04212026 2023-07-18
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
University Hospital, Basel, Switzerland
Phase 2 Terminated
NCT04361162 2022-09-08
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04258150 2022-03-31
TRIPPLE-R
Herlev Hospital
Phase 2 Terminated
NCT03599362 2021-10-19
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
NYU Langone Health
Phase 2 Terminated
NCT04377048 2020-05-06
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
National Taiwan University Hospital
Phase 2 Unknown